Full Press Release Details
Announces Proposed Effective Date of Share Consolidation
and VANCOUVER, British Columbia, Aug. 21, 2025 (GLOBE NEWSWIRE) - BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX:
BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel
immunotherapies to transform cancer care announced today that the Company's board of directors has approved the consolidation (the
"Consolidation") of the Company's issued and outstanding common shares (the "Common Shares")
on the basis of one (1) post-Consolidation Common Share for every ten (10) pre-Consolidation Common Shares. The Consolidation is being
implemented to ensure that the Company continues to comply with the listing requirements of The Nasdaq Capital Market (the "Nasdaq").
Consolidation is subject to approval by the Toronto Stock Exchange (the "TSX") and Nasdaq and is expected to become
effective on August 25, 2025 (the "Effective Date"), with the post-Consolidation Common Shares commencing trading
on the TSX and the Nasdaq at market open on or about August 25, 2025, subject to final confirmation from the TSX and the Nasdaq. No fractional
Common Shares will be issued in connection with the Consolidation. Any fractional Common Shares remaining after the Consolidation that
are less than ½ of a Common Share will be cancelled, and each fractional Common Share that is at least ½ of a Common Share
will be rounded up to one whole Common Share. The Company does not intend to round up fractional shares at the beneficial level and will
instead round any such fractional shares up at the participant level. The exercise or conversion price and/or the number of Common Shares
issuable under any of the Company's outstanding convertible securities will be proportionately adjusted in connection with the
is anticipated that upon completion of the Consolidation, the post-Consolidation Common Shares will continue to trade on the TSX under
the symbol "BCT" and on the Nasdaq under the symbol "BCTX".
of record as of the Effective Date will receive a letter of transmittal from Computershare Investor Services Inc., the transfer agent
for the Common Shares, providing instructions for the exchange of their Common Shares as soon as practicable following the Effective
shareholders may also obtain a copy of the letter of transmittal by accessing the Company's SEDAR+ profile at www.sedarplus.ca.
Until surrendered, each share certificate or direct registration system statement representing pre-Consolidation Common Shares will represent
the number of whole post-Consolidation Common Shares to which the holder is entitled as a result of the Consolidation. No action is required
by beneficial holders to receive post-Consolidation Common Shares in connection with the Consolidation. Beneficial holders who hold their
Common Shares through intermediaries (e.g., a broker, bank, trust company investment dealer or other financial institution) and who have
questions regarding how the Consolidation will be processed should contact their intermediaries with respect to the Consolidation.
BriaCell Therapeutics Corp.
is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available
press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements
contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate,"
"could," "estimate," "expect," "intend," "seek," "may," "might,"
"plan," "potential," "predict," "project," "target," "aim," "should,"
"will," "would," or the negative of these words or other similar expressions, although not all forward-looking
statements contain these words. Forward-looking statements are based on BriaCell's current expectations and are subject to inherent
uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements, such as those are based
on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully
under the heading "Risks and Uncertainties" in the Company's most recent Management's Discussion and Analysis,
under the heading "Risk Factors" in the Company's most recent Annual Information Form, and under "Risks and Uncertainties"
in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission,
all of which are available under the Company's profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov.
Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty
to update such information except as required under applicable law.
the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange)
accepts responsibility for the adequacy or accuracy of this release.
William V. Williams, MD